Inari Medical (NASDAQ:NARI) Stock, Quote.Headers.trade-ideas

Inari Medical

Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from Chronic Venous Disease. Its product portfolio includes; ClotTriever, for the removal of the clot from peripheral blood vessels and treats patients suffering from deep vein thrombosis. The FlowTriever System product is used for the treatment of pulmonary embolism, InThrill system to treat small vessel thrombosis, LimFlow system and others. Geographically, the company generates majority of its revenue from United States and rest from International markets.

NARI

News

Health Care

General

The FDA labels Inari Medical&#39;s ClotTriever catheter recall as the most serious, citing risks like device entrapment and pulmonary emboli, linked to injuries and deaths.

FDA Classifies Recall Of Inari Medical&#39;s Large Vessel Clot Removal Catheter Device As Most Serious

Earnings

Earnings Misses

Guidance

Markets

Analyst Ratings

Trading Ideas

HOLX

Inari Medical, Inc. (NASDAQ: NARI) reported an adjusted loss per share of 41 cents in the second quarter of 2024 compared with the year-ago period&#39;s loss of 4 cents per share. The Zacks Consensus Estimate for loss per share was pegged at 16 cents.

Inari Medical Q2 Earnings Miss, Revenues Increase Y/Y

ALGN

Inari Medical (NASDAQ: NARI) continues to ride on the success of its ClotTriever and FlowTriever products available for treating venous thromboembolism (VTE).

Inari&#39;s Expanding Product Portfolio Offsets Competition

Inari Medical Inc

WIIM

TechnipFMC shares are trading higher after the company announced it was rewarded two contracts by the Petrobas for Brazil's pre-salt fields. The first contract is between $250 million to $500 million and the second is ranges from $75 million to $250 million.

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Starbucks</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with SBUX, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 8 uncommon options trades for Starbucks.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 50% bullish and 25%, bearish.</p>
<p>Out of all of the special options we uncovered, 4 are puts, for a total amount of $130,757, and 4 are calls, for a total amount of $147,345.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $85.0 to $125.0 for Starbucks over the last 3 months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Starbucks's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Starbucks's whale trades within a strike price range from $85.0 to $125.0 in the last 30 days. </p>
<h3>Starbucks 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726857591_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>SBUX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$13.6</td>
<td>$12.4</td>
<td>$13.05</td>
<td>$85.00</td>
<td>$48.2K</td>
<td>614</td>
<td style="text-align: right;">60</td>
</tr>
<tr>
<td>SBUX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$3.1</td>
<td>$3.0</td>
<td>$3.05</td>
<td>$95.00</td>
<td>$45.7K</td>
<td>8.1K</td>
<td style="text-align: right;">464</td>
</tr>
<tr>
<td>SBUX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$10.35</td>
<td>$9.75</td>
<td>$9.9</td>
<td>$85.00</td>
<td>$39.6K</td>
<td>550</td>
<td style="text-align: right;">40</td>
</tr>
<tr>
<td>SBUX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/01/24</td>
<td>$5.75</td>
<td>$5.55</td>
<td>$5.55</td>
<td>$100.00</td>
<td>$33.3K</td>
<td>3</td>
<td style="text-align: right;">61</td>
</tr>
<tr>
<td>SBUX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$12.35</td>
<td>$11.9</td>
<td>$11.9</td>
<td>$100.00</td>
<td>$32.1K</td>
<td>103</td>
<td style="text-align: right;">105</td>
</tr>
</tbody>
</table>
</p>
<h3>About Starbucks</h3>
<p>Starbucks is one of the most widely recognized restaurant brands in the world, operating more than 38,000 stores across more than 80 countries as of the end of fiscal 2023. The firm operates in three segments: North America, international markets, and channel development (grocery and ready-to-drink beverage). The coffee chain generates revenue from company-operated stores, royalties, sales of equipment and products to license partners, ready-to-drink beverages, packaged coffee sales, and single-serve products.</p>
<p>Following our analysis of the options activities associated with Starbucks, we pivot to a closer look at the company's own performance.</p>
<h3>Current Position of Starbucks</h3>
<ul>
<li>Trading volume stands at 5,259,380, with SBUX's price down by -0.09%, positioned at $96.81.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 41 days.</li>
</ul>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Starbucks options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Options

SBUX

Check Out What Whales Are Doing With SBUX

<p>High-rolling investors have positioned themselves bearish on Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), and it's important for retail traders to take note.<br />
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in GILD often signals that someone has privileged information.</p>
<p>Today, Benzinga's options scanner spotted 9 options trades for Gilead Sciences. This is not a typical pattern.</p>
<p>The sentiment among these major traders is split, with 22% bullish and 55% bearish. Among all the options we identified, there was one put, amounting to $35,055, and 8 calls, totaling $278,552.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $75.0 to $87.5 for Gilead Sciences during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In today's trading context, the average open interest for options of Gilead Sciences stands at 445.5, with a total volume reaching 2,234.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Gilead Sciences, situated within the strike price corridor from $75.0 to $87.5, throughout the last 30 days.</p>
<h3>Gilead Sciences Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726857586_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$8.9</td>
<td>$8.8</td>
<td>$8.8</td>
<td>$75.00</td>
<td>$41.2K</td>
<td style="text-align: right;">867</td>
<td style="text-align: right;">61</td>
</tr>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$8.85</td>
<td>$8.75</td>
<td>$8.73</td>
<td>$75.00</td>
<td>$38.4K</td>
<td style="text-align: right;">867</td>
<td style="text-align: right;">343</td>
</tr>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$9.45</td>
<td>$8.8</td>
<td>$8.83</td>
<td>$75.00</td>
<td>$36.1K</td>
<td style="text-align: right;">867</td>
<td style="text-align: right;">141</td>
</tr>
<tr>
<td>GILD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$6.25</td>
<td>$6.15</td>
<td>$6.15</td>
<td>$87.50</td>
<td>$35.0K</td>
<td style="text-align: right;">24</td>
<td style="text-align: right;">58</td>
</tr>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$8.75</td>
<td>$8.6</td>
<td>$8.6</td>
<td>$75.00</td>
<td>$34.3K</td>
<td style="text-align: right;">867</td>
<td style="text-align: right;">506</td>
</tr>
</tbody>
</table>
</p>
<h3>About Gilead Sciences</h3>
<p>Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).</p>
<p>After a thorough review of the options trading surrounding Gilead Sciences, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Gilead Sciences's Current Market Status</h3>
<ul>
<li>Trading volume stands at 7,413,669, with GILD's price down by -0.71%, positioned at $83.31.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 48 days.</li>
</ul>
<h3>What The Experts Say On Gilead Sciences</h3>
<p>4 market experts have recently issued ratings for this stock, with a consensus target price of $77.25.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Sector Perform rating on Gilead Sciences with a target price of $74.<br />
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Neutral with a new price target of $70.<br />
&#x2A; An analyst from Piper Sandler has decided to maintain their Overweight rating on Gilead Sciences, which currently sits at a price target of $95.<br />
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Neutral, adjusting the price target to $70. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Gilead Sciences options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


GILD

Gilead Sciences Unusual Options Activity For September 20

<p>Deep-pocketed investors have adopted a bearish approach towards AppLovin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in APP usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options activities for AppLovin. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 36% leaning bullish and 54% bearish. Among these notable options, 5 are puts, totaling $699,984, and 6 are calls, amounting to $278,842.</p>
<h3>What's The Price Target?</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $100.0 and $140.0 for AppLovin, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for AppLovin's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of AppLovin's whale trades within a strike price range from $100.0 to $140.0 in the last 30 days. </p>
<h3>AppLovin Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726857580_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>APP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$7.4</td>
<td>$7.2</td>
<td>$7.37</td>
<td>$110.00</td>
<td>$283.9K</td>
<td>640</td>
<td>416</td>
</tr>
<tr>
<td>APP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$13.6</td>
<td>$13.5</td>
<td>$13.5</td>
<td>$130.00</td>
<td>$182.2K</td>
<td>19</td>
<td>0</td>
</tr>
<tr>
<td>APP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$8.6</td>
<td>$8.4</td>
<td>$8.4</td>
<td>$120.00</td>
<td>$168.0K</td>
<td>403</td>
<td>268</td>
</tr>
<tr>
<td>APP</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$28.2</td>
<td>$27.5</td>
<td>$27.6</td>
<td>$105.00</td>
<td>$69.0K</td>
<td>1.8K</td>
<td>27</td>
</tr>
<tr>
<td>APP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$1.2</td>
<td>$1.15</td>
<td>$1.15</td>
<td>$125.00</td>
<td>$56.2K</td>
<td>9.5K</td>
<td>1.2K</td>
</tr>
</tbody>
</table>
</p>
<h3>About AppLovin</h3>
<p>AppLovin Corp is a mobile app technology company. It focuses on growing the mobile app ecosystem by enabling the success of mobile app developers. The company's software solutions provide tools for mobile app developers to grow their businesses by automating and optimizing the marketing and monetization of their applications.</p>
<p>In light of the recent options history for AppLovin, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Where Is AppLovin Standing Right Now?</h3>
<ul>
<li>With a trading volume of 2,364,096, the price of APP is up by 1.23%, reaching $125.53.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 47 days from now.</li>
</ul>
<h3>Expert Opinions on AppLovin</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $127.2.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Citigroup persists with their Buy rating on AppLovin, maintaining a target price of $155.<br />
&#x2A; An analyst from B of A Securities has decided to maintain their Buy rating on AppLovin, which currently sits at a price target of $120.<br />
&#x2A; Showing optimism, an analyst from UBS upgrades its rating to Buy with a revised price target of $145.<br />
&#x2A; An analyst from BTIG has decided to maintain their Buy rating on AppLovin, which currently sits at a price target of $150.<br />
&#x2A; Maintaining their stance, an analyst from Benchmark continues to hold a Sell rating for AppLovin, targeting a price of $66. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest AppLovin options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


This Is What Whales Are Betting On AppLovin

<p>This week has been a bit down in general and in regards to the technology sector, particularly companies focused on <a href="https://www.benzinga.com/topic/artificial-intelligence">artificial intelligence (AI),</a><strong> </strong>has once again taken front and center stage in the stock market. Industry giants like Nvidia <strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</strong>, <a href="https://www.benzinga.com/quote/MSFT">Microsoft </a>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), and Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) have seen their stocks experience notable fluctuations, driven by a mix of optimism around AI&#8217;s potential and concerns over high valuations.</p>
<p>In recent months, AI has become one of the hottest trends on Wall Street. With tech companies integrating AI into various products and services, investors are eager to capitalize on this technological revolution. However, the enthusiasm is also being met with caution as analysts weigh the sustainability of current valuations and where this market my be headed. .</p>
<h3 class="wp-block-heading">Nvidia&#8217;s Continued AI Boom Seems To Be Neverending</h3>
<h4 class="wp-block-heading">Strong Demand For AI Chips</h4>
<p>One of the biggest players in the AI space, Nvidia, has been benefiting significantly from the high demand for its graphics processing units (GPUs). These chips are essential in powering advanced AI systems, including those used in machine learning and neural networks. Nvidia's position as a leader in AI chips has been solidified as companies and institutions increasingly adopt AI technologies and the need for companies to show they are utilizing advancements in AI is strong.</p>
<p>That being said,  this surge in demand comes with its own set of challenges. While Nvidia's stock has soared throughout 2023, this week has seen increased volatility, which has lead to concerns about whether the company's stock price can continue to rise at such a rapid pace. Some analysts are beginning to voice caution, noting that the stock may be overvalued in the short term, even if the long-term outlook remains strong.</p>
<h4 class="wp-block-heading">Valuation Concerns</h4>
<p>Despite Nvidia's dominance, the company&#8217;s high stock price is attracting skepticism. Investors are concerned about whether Nvidia&#8217;s current valuation is justified or whether the stock has surged too far, too fast. Many see the current price as a reflection of market hype around AI rather than the company&#8217;s actual financial performance.</p>
<h3 class="wp-block-heading">Microsoft and OpenAI partnership</h3>
<h4 class="wp-block-heading">Expanding AI Services</h4>
<p><strong>Microsoft</strong> is another tech giant that has ridden the AI wave, particularly through its investment in OpenAI, the company behind <strong>ChatGPT</strong>. Microsoft has not only integrated AI into its own product offerings but has also enabled other businesses to access powerful AI tools through its cloud services. As a result, <a href="https://www.benzinga.com/news/24/09/40931968/microsofts-linkedin-in-hot-water-for-allegedly-using-data-of-users-for-training-ai-before-updating-t">Microsoft's </a>stock has continued to perform well, benefiting from the excitement surrounding AI's practical applications in industries ranging from healthcare to finance.</p>
<h4 class="wp-block-heading">Market Response</h4>
<p>This week, Microsoft's stock has seen steady movement, driven by announcements of further AI integration into its cloud infrastructure and software services. Microsoft's dominance in both cloud computing and AI has put it in a position to lead the market, but as with Nvidia, there are concerns about whether the stock is overvalued due to AI hype.</p>
<h3 class="wp-block-heading">Alphabet's Role in the AI Race</h3>
<h4 class="wp-block-heading">Google's AI Innovations</h4>
<p>Not to be outdone, Alphabet (Google) is also a major player in the AI space. Google's work on AI technologies such as Google Bard and AI-driven search algorithms has kept the company in the spotlight. This week, Alphabet has faced a mix of optimism and caution. On one hand, the company is expected to remain a key player in AI for years to come. On the other, like Nvidia and Microsoft, Alphabet is grappling with regulatory concerns and skepticism about overvaluation.</p>
<h4 class="wp-block-heading">Regulation And Oversight</h4>
<p>The increasing reliance on AI has attracted the attention of governments worldwide. Alphabet, along with other tech giants, faces growing pressure to ensure that AI is developed and deployed responsibly. Concerns around data privacy, AI's potential to disrupt industries, and the ethical implications of AI-driven decision-making are hot topics. As a result, Alphabet's stock, while generally positive this week, has been influenced by regulatory discussions.</p>
<h3 class="wp-block-heading">Conclusion: Volatility And Opportunity</h3>
<p>This week's movements in AI stocks reflect the broader uncertainty in the tech market. While companies like Nvidia, Microsoft, and Alphabet are positioned to lead the AI revolution, investors must weigh the <strong>risks of overvaluation</strong> and the potential for regulatory changes against the long-term benefits AI is poised to deliver.</p>
<p>The story of AI in tech stocks is far from over, and as the technology continues to evolve, so too will the market's reaction. For now, both excitement and caution remain key themes in this rapidly developing space.</p>


Tech

GOOGL

MSFT

NVDA

The Ups And Downs Of AI Stocks This Week

Vistra shares are trading higher after BMO Capital raised its price target on the stock from $120 to $125. The stock is also moving higher in sympathy with the nuclear and uranium industry.

Insider Trades

GLMD

Masaya Otsuka Reported a 9.9% Passive Stake In Galmed Pharmaceuticals In A 13G Filing

ENFN

Enfusion shares are trading higher after the company announced it is interviewing investment banks to explore options including a potential sale.

<p>It has been about a month since the last earnings report for <strong>Zoom Video Communications</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zm#NASDAQ">ZM</a>). Shares have lost about 1.7% in that time frame, underperforming the S&amp;P 500.</p>
<p>Will the recent negative trend continue leading up to its next earnings release, or is Zoom Video due for a breakout? Before we dive into how investors and analysts have reacted as of late, let&#39;s take a quick look at the most recent earnings report in order to get a better handle on the important drivers.</p>
<h3>Zoom Q2 Earnings Beat, Enterprise Customers Drive Revenues</h3>
<p>Zoom&#39;s second-quarter fiscal 2025 adjusted earnings of $1.39 per share beat the Zacks Consensus Estimate by 14.88% and increased 3.73% year over year.</p>
<p>Revenues of $1.16 billion beat the consensus mark by 1.22% and increased 2.09% year over year on strong growth from Enterprise customers. Adjusting for foreign currency impact, revenues in constant currency were $1.166 billion, up 2.4% year over year.</p>
<h3>Quarter Details</h3>
<p>Enterprise revenues were $682.8 million, up 3.5% year over year and represented 58.7% of total revenues. Customers contributing more than $100,000 in revenues in the trailing 12 months grew 7% to 3,933. These customers accounted for 31% of revenues, up from 29% in the year-ago quarter.</p>
<p>In the fiscal second quarter, as part of an effort to improve the customer experience and drive greater efficiency in operations, the company transitioned 26,800 Enterprise customers with low annualized revenue run rate&nbsp;to Online.</p>
<p>The number of Enterprise customers at the end of the second quarter, after accounting for the transition, was approximately 191,600.</p>
<p>The company reported a trailing 12-month net dollar expansion rate for Enterprise customers of 98%.</p>
<p>As of the end of the quarter under review, the cumulative number of Zoom Rooms licenses purchased was more than 2 million.</p>
<p>In the quarter, Zoom saw amazing traction with Workvivo as it reached 69 customers with more than $100,000 in ARR, roughly doubling year over year. Workvivo was named Meta Platform&#39;s only preferred migration partner for its customers as it retires Workplace from Meta.</p>
<p>ZM witnessed additional traction in Zoom Contact Center as it surpassed 1,100 Zoom Contact Center customers, representing more than 100% year-over-year growth. This was driven by its recently launched higher pricing tiers as well as its success in larger deals.</p>
<p>The company now has five customers with 100,000 or more Zoom Phone seats. Zoom AI Companion has grown significantly with more than 1.2 million customer accounts enabled as of date.</p>
<h3>Non-GAAP Operating Details</h3>
<p>Non-GAAP gross margin in the fiscal second quarter was 78.6%, which was slightly lower than 80.3% in the year-ago period, mainly due to investments in AI innovation.</p>
<p>Research and development expenses increased 7.8% year over year to $206.7 million. Sales and marketing expenses declined 3.9% to $358.7 million, while general and administrative expenses plunged 15.3% to $109.5 million.</p>
<p>Operating income rose 13.9% to $202.37 million year over year. The operating margin came in at 17.6% compared with the year-ago quarter&#39;s operating margin of 15.9%.</p>
<h3>Balance Sheet</h3>
<p>Total cash, cash equivalents and marketable securities, as of Jul 31, 2024, were $7.5 billion.&nbsp; As of Apr 30, 2024, cash, cash equivalents and marketable securities were $7.4 billion.</p>
<p>Net cash provided by operating activities was $449.3 million for the fiscal second quarter, up 33.7% year over year. Free cash flow was $365.1 million, up 26.2% year over year.</p>
<h3>Guidance</h3>
<p>Zoom expects third-quarter fiscal 2025 revenues between $1,162 million and $1,165 million.</p>
<p>Non-GAAP earnings per share are expected in the range of $1.29-$1.31.</p>
<p>For fiscal 2025, Zoom expects revenues in the range of $4.63-$4.64 billion.</p>
<p>Non-GAAP earnings per share are expected in the band of $5.29-$5.32.</p>
<h2>How Have Estimates Been Moving Since Then?</h2>
<p>It turns out, fresh estimates have trended upward during the past month.</p>
<p>The consensus estimate has shifted 12.46% due to these changes.</p>
<h2>VGM Scores</h2>
<p>At this time, Zoom Video has an average Growth Score of C, however its Momentum Score is doing a lot better with an A. However, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.</p>
<p>Overall, the stock has an aggregate VGM Score of B. If you aren&#39;t focused on one strategy, this score is the one you should be interested in.</p>
<h2>Outlook</h2>
<p>Estimates have been trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Zoom Video has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.</p>
<h2>Performance of an Industry Player</h2>
<p>Zoom Video is part of the Zacks Internet - Software industry. Over the past month, <strong>HubSpot</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hubs#NYSE">HUBS</a>), a stock from the same industry, has gained 6.7%. The company reported its results for the quarter ended June 2024 more than a month ago.</p>
<p>HubSpot reported revenues of $637.23 million in the last reported quarter, representing a year-over-year change of +20.4%. EPS of $1.94 for the same period compares with $1.34 a year ago.</p>
<p>For the current quarter, HubSpot is expected to post earnings of $1.89 per share, indicating a change of +18.9% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.</p>
<p>The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for HubSpot. Also, the stock has a VGM Score of B.</p>
<p><a href="https://www.zacks.com/stock/news/2339316/zoom-video-zm-down-1-7-since-last-earnings-report-can-it-rebound?cid=CS-BENZ-FT-realtime_blog-2339316">To read this article on Zacks.com click here.</a></p>


Earnings Beats

Large Cap

Small Cap

HUBS

Zoom Video Down 1.7% Since Last Earnings Report: Can It Rebound?

<p>Equifax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFX#NYSE">EFX</a>) has outperformed the market over the past 20 years by 4.48% on an annualized basis producing an average annual return of 12.97%. Currently, Equifax has a market capitalization of $37.39 billion. </p>
<p><strong>Buying $1000 In EFX:</strong> If an investor had bought $1000 of EFX stock 20 years ago, it would be worth <strong>$11,290.99</strong> today based on a price of $302.19 for EFX at the time of writing.</p>
<h3>Equifax's Performance Over Last 20 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726857087_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$1000 Invested In This Stock 20 Years Ago Would Be Worth $11,000 Today

<p>Deckers Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) has outperformed the market over the past 20 years by 16.43% on an annualized basis producing an average annual return of 24.91%. Currently, Deckers Outdoor has a market capitalization of $22.82 billion. </p>
<p><strong>Buying $1000 In DECK:</strong> If an investor had bought $1000 of DECK stock 20 years ago, it would be worth <strong>$85,940.67</strong> today based on a price of $149.68 for DECK at the time of writing.</p>
<h3>Deckers Outdoor's Performance Over Last 20 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726857082_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


DECK

Here's How Much $1000 Invested In Deckers Outdoor 20 Years Ago Would Be Worth Today

<p>Despite a wider market pullback, the <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40930136/expert-says-the-future-of-defi-will-be-shaped-by-fintechs-like-revolut-and-robinhood-not-w">total value locked (TVL) in DeF</a>i on <strong>Core</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">CORE</a>), <strong>Bitcoin</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) Layer-2 blockchain, has grown significantly in the second quarter of 2024.</p>
<p><strong>What Happened: </strong>According to a Messari report, Core&#8217;s DeFi TVL grew by 1,032% in Q2, reaching $76.4 million. The blockchain&#8217;s native decentralized exchange (DEX) CoreX outperformed SushiSwap, a multi-chain DEX.</p>
<p>Non-custodial bitcoin staking, launched on Core's platform in April, saw 3,504 BTC, equivalent to $215 million, staked in Q2, broadening investor access and exposure to Core.</p>
<p>Valour, a subsidiary of DeFi Technologies, introduced a unique yield-bearing Core BTC exchange-traded product (ETP) to German investors on the Frankfurt stock exchange in June. This initiative offers users a 5.65% yield in addition to Bitcoin exposure.</p>
<p>Core and Valour have since listed other BTC ETPs on Sweden's Spotlight Stock Market and the London Stock Exchange.</p>
<p><figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure></p>
<p><strong>Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40734905/blockchain-core-foundation-launches-liquid-staking-token-pegged-against-bitcoin">Blockchain Core Foundation Launches Liquid Staking Token Pegged Against Bitcoin</a></strong></p>
<p><strong>Why it Matters: </strong>Secured by and aligned with Bitcoin, Core&#8217;s blockchain is unlocking over $1.25 trillion in trapped Bitcoin liquidity. The platform hosts over 100 Dapps, enabling Bitcoin holders to utilize their Bitcoin in innovative ways.</p>
<p>The significant growth in DeFi TVL and the introduction of non-custodial BTC staking underscore Core&#8217;s commitment to providing diverse investment opportunities and enhancing investor access. </p>
<p>The listing of BTC ETPs on various stock exchanges also reflects Core&#8217;s expanding global presence and its efforts to offer investors yield-bearing opportunities in addition to Bitcoin exposure.</p>
<p>Rich Rines, an Initial Contributor to Core, noted that demand for Bitcoin staking and Core DeFi is increasing, commenting, &#8220;The first quarter with live Non-Custodial Bitcoin Staking represents a new epoch for Bitcoin, powered by Core.&#8221; </p>
<p><strong>What&#8217;s Next</strong>: The influence of&nbsp;<a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a>&nbsp;is expected to be thoroughly explored at Benzinga&#8217;s upcoming&nbsp;<a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a>&nbsp;event on Nov. 19.</p>
<p><strong>Read Next:&nbsp;</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40961891/blockchains-global-expansion-insights-from-an-interview-with-korea-blockchain-weeks-founde">Blockchain&#8217;s Global Expansion: Insights From An Interview With Korea Blockchain Week&#8217;s Founder</a></strong></li>
</ul>
<p><em>Image created using artificial intelligence with Midjourney.</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$CORE

Core Blockchain's DeFi TVL Skyrockets Over 1000%, Introduces Non-Custodial BTC Staking

<p>It has been about a month since the last earnings report for <strong>Wolfspeed</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wolf#NYSE">WOLF</a>). Shares have lost about 31.3% in that time frame, underperforming the S&amp;P 500.</p>
<p>Will the recent negative trend continue leading up to its next earnings release, or is Wolfspeed due for a breakout? Before we dive into how investors and analysts have reacted as of late, let&#39;s take a quick look at the most recent earnings report in order to get a better handle on the important drivers.</p>
<h3>Wolfspeed Reports Loss in Q4 Earnings, Revenues Down Y/Y</h3>
<p>Wolfspeed reported a fourth-quarter fiscal 2024 non-GAAP loss of 89 cents per share, wider than the Zacks Consensus Estimate of a loss of 84 cents per share but narrower than the year-ago quarter&#39;s loss of 36 cents per share.</p>
<p>Revenues of $200.7 million decreased 1% year over year but lagged the consensus mark by 0.2%. Mohawk Valley Fab contributed $41 million in revenues in the reported quarter.</p>
<p>Power Products accounted for 52.1%, while Materials Products contributed 47.9%. Power Products revenues decreased 2.3% year over year to $104.6 million. Materials Products revenues increased 0.5% year over year to $96.1 million.</p>
<p>Power device design-ins were $2 billion in the reported quarter. Quarterly design wins were $0.5 billion.</p>
<h3>Wolfspeed&#39;s Operating Details</h3>
<p>For the fiscal fourth quarter, Wolfspeed reported a non-GAAP gross margin of 5.4%, down from 30.7% reported in the year-ago quarter. Underutilization costs of $24 million negatively impacted gross margin in the reported quarter.</p>
<p>In the reported quarter, sales, general and administrative expenses were $60 million (29.9% of total revenues), up 37.6% year over year.</p>
<p>Research &amp; development expenses (30.7% of total revenues) increased 4.8% year over year to $61.6 million.</p>
<p>Wolfspeed incurred $20.5 million in factory start-up costs in the fourth quarter of fiscal 2024.</p>
<p>The company incurred a non-GAAP operating loss of $118.9 million, wider than the operating loss of $66.8 million in the year-ago quarter.</p>
<h3>WOLF&#39;s Balance Sheet &amp; Cash Flow</h3>
<p>As of Jun 30, 2024, WOLF had cash, cash equivalents and short-term investments of $2.17 billion compared with $2.55 billion as of Mar 31, 2024.</p>
<p>Long-term debt was $3.13 billion as of Jun 30, 2024.</p>
<p>Free cash outflow was $885.3 million, comprising $239.5 million of operating cash outflow and $644.2 million of capital expenditures.</p>
<h3>Guidance</h3>
<p>For first-quarter fiscal 2025, Wolfspeed expects revenues in the range of $185-$215 million. Non-GAAP loss is expected between 90 cents and $1.09 per share.</p>
<p>The company expects Mohawk Valley Fab to contribute nearly $20-$30 million in revenues in the first quarter of fiscal 2025.</p>
<p>It expects non-GAAP gross margin in the range of 13-20%. Non-GAAP operating expenses are expected to be $109 million, including $13 million of start-up costs.</p>
<h2>How Have Estimates Been Moving Since Then?</h2>
<p>In the past month, investors have witnessed a downward trend in fresh estimates.</p>
<p>The consensus estimate has shifted -11.14% due to these changes.</p>
<h2>VGM Scores</h2>
<p>At this time, Wolfspeed has a poor Growth Score of F, a grade with the same score on the momentum front. Following the exact same course, the stock was allocated a grade of F on the value side, putting it in the bottom 20% quintile for this investment strategy.</p>
<p>Overall, the stock has an aggregate VGM Score of F. If you aren&#39;t focused on one strategy, this score is the one you should be interested in.</p>
<h2>Outlook</h2>
<p>Estimates have been trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Wolfspeed has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.</p>
<p><a href="https://www.zacks.com/stock/news/2339315/why-is-wolfspeed-wolf-down-31-3-since-last-earnings-report?cid=CS-BENZ-FT-realtime_blog-2339315">To read this article on Zacks.com click here.</a></p>


WOLF

Why Is Wolfspeed Down 31.3% Since Last Earnings Report?

<p>A month has gone by since the last earnings report for <strong>Macy&#39;s</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/m#NYSE">M</a>). Shares have added about 1.1% in that time frame, underperforming the S&amp;P 500.</p>
<p>Will the recent positive trend continue leading up to its next earnings release, or is Macy&#39;s due for a pullback? Before we dive into how investors and analysts have reacted as of late, let&#39;s take a quick look at the most recent earnings report in order to get a better handle on the important drivers.</p>
<h3>Macy&#39;s Q2 Earnings Beat Estimates, Comps Decline Y/Y</h3>
<p>Macy&#39;s has reported second-quarter fiscal 2024 results, wherein the top line lagged the Zacks Consensus Estimate while the bottom line surpassed the same. Total revenues declined and earnings increased from the year-ago quarter&#39;s reported figures. Comparable sales (comps) fell on an owned basis and an owned-plus-licensed basis.</p>
<h3>Sales &amp; Earnings Picture</h3>
<p>Macy&#39;s has reported adjusted earnings of 53 cents per share, surpassing the Zacks Consensus Estimate of 32 cents. Also, the bottom line increased from 23 cents in the year-ago period.</p>
<p>Net sales of $4,937 million missed the consensus estimate of $5,091 million. Also, the top line dipped 3.8% from the year-ago quarter. Comps fell 4% on an owned basis and 3.3% on an owned-plus-licensed-plus-marketplace basis from the prior-year quarter.</p>
<p>Macy&#39;s ongoing business comps, including both go-forward locations and digital platforms across all nameplates, decreased 3.8% on an owned basis and 3% when including owned, licensed and marketplace channels.</p>
<p>Net credit card revenues were $125 million, up 4.2% from the year-ago period. The metric represented 2.5% of sales, up 20 basis points from the year-ago quarter.</p>
<h3>Details by Brands</h3>
<p>Comps across Macy&#39;s declined 4.5% year over year on an owned basis and 3.6% on an owned-plus-licensed-plus-marketplace basis. At the Bloomingdale&#39;s brand, comps decreased 1.1% on an owned basis and 1.4% on an owned-plus-licensed-plus-marketplace basis. Comps at the Bluemercury brand rose 2% on an owned basis.</p>
<h3>Margins</h3>
<p>The gross margin was 40.5%. The metric increased 240 basis points from 38.1% in the prior-year quarter. The merchandise margin increased 210 basis points primarily due to reduced year-over-year discounting, favorable inventory shortages resulting from the company&#39;s asset protection efforts and M&#39;s transition to cost accounting.</p>
<p>Delivery expenses as a percentage of net sales improved year over year by 30 basis points, driven by lower shipped sales volumes and enhanced delivery expense management, reflecting cost-saving measures and process re-engineering initiatives.</p>
<p>The company reported selling, general and administrative (SG&amp;A) expenses of $1.97 billion, down 0.4% from $1.98 billion in the year-ago period. As a percentage of net sales, SG&amp;A expenses increased 140 basis points year over year to 40% on lower net sales.</p>
<p>Macy&#39;s reported an adjusted EBITDA of $438 million, up 26.2% from an adjusted EBITDA of $347 million in the year-ago quarter. We note that the adjusted EBITDA margin was 8.9%, up 210 basis points year over year.</p>
<h3>Other Financial Aspects</h3>
<p>M ended the fiscal second quarter with cash and cash equivalents of $646 million, long-term debt of $2.99 billion, and shareholders&#39; equity of $4.30 billion. Merchandise inventories rose 6% on a year-over-year basis. In the second quarter of fiscal 2024, Macy&#39;s provided cash from operating activities of $137 million.</p>
<h3>A Peek Into Guidance</h3>
<p>The company has revised its annual outlook to account for more cautious consumers and a more intense promotional environment than previously anticipated. This updated outlook is intended to provide the flexibility needed to navigate the continued uncertainty in the discretionary consumer market. M has reaffirmed its annual adjusted earnings per share outlook.</p>
<p>However, Macy&#39;s continues to see fiscal 2024 as a transitional and investment year, focusing on key strategic initiatives to improve customer experience. With the support of a strong balance sheet, the company will prioritize enhancing its gross margin and maintaining expense control to safeguard profitability amid ongoing macroeconomic challenges.</p>
<p>Net sales are projected to be $22.1-$22.4 billion, a slight reduction from the previously stated $22.3-$22.9 billion. Notably, the company reported net sales of $23.1 billion in fiscal 2023.</p>
<p>The outlook for comparable owned-plus-licensed-plus-marketplace sales on a 52-week basis has also been adjusted, with a projected year-over-year decline of 0.5-2%, down from the previously stated range between a drop of 1% and an increase of 1.5%.</p>
<p>Adjusted earnings per share are envisioned to be $2.55-$2.90 for fiscal 2024, implying a decline from the $3.50 earned in the prior year.</p>
<h2>How Have Estimates Been Moving Since Then?</h2>
<p>It turns out, fresh estimates have trended downward during the past month.</p>
<p>The consensus estimate has shifted -100% due to these changes.</p>
<h2>VGM Scores</h2>
<p>Currently, Macy&#39;s has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with a D. However, the stock was allocated a grade of A on the value side, putting it in the top 20% for this investment strategy.</p>
<p>Overall, the stock has an aggregate VGM Score of A. If you aren&#39;t focused on one strategy, this score is the one you should be interested in.</p>
<h2>Outlook</h2>
<p>Estimates have been broadly trending downward for the stock, and the magnitude of these revisions has been net zero. It&#39;s no surprise Macy&#39;s has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months.</p>
<h2>Performance of an Industry Player</h2>
<p>Macy&#39;s belongs to the Zacks Retail - Regional Department Stores industry. Another stock from the same industry, <strong>Dillard&#39;s</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dds#NYSE">DDS</a>), has gained 6.1% over the past month. More than a month has passed since the company reported results for the quarter ended July 2024.</p>
<p>Dillard&#39;s reported revenues of $1.49 billion in the last reported quarter, representing a year-over-year change of -4.9%. EPS of $4.59 for the same period compares with $7.98 a year ago.</p>
<p>Dillard&#39;s is expected to post earnings of $6.47 per share for the current quarter, representing a year-over-year change of -30.4%. Over the last 30 days, the Zacks Consensus Estimate has changed -4.2%.</p>
<p>Dillard&#39;s has a Zacks Rank #4 (Sell) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of C.</p>
<p><a href="https://www.zacks.com/stock/news/2339317/macy-s-m-up-1-1-since-last-earnings-report-can-it-continue?cid=CS-BENZ-FT-realtime_blog-2339317">To read this article on Zacks.com click here.</a></p>


Mid Cap

Retail Sales

Macy's Up 1.1% Since Last Earnings Report: Can It Continue?

BDRX

Biodexa Pharmaceuticals shares are trading lower. The company announced a ratio change on its ADRs from one ADS unit representing 400 ordinary shares to representing 10,000 ordinary shares.

Federal Reserve

Philadelphia Fed President Harker Said Fed Has Done A Good Job Navigating Economy

<p>Deep-pocketed investors have adopted a bullish approach towards Newmont (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in NEM usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 16 extraordinary options activities for Newmont. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 75% leaning bullish and 25% bearish. Among these notable options, 5 are puts, totaling $1,067,840, and 11 are calls, amounting to $482,689.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $47.5 to $60.0 for Newmont over the last 3 months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In today's trading context, the average open interest for options of Newmont stands at 7940.17, with a total volume reaching 9,484.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Newmont, situated within the strike price corridor from $47.5 to $60.0, throughout the last 30 days.</p>
<h3>Newmont 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726856293_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>NEM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$0.99</td>
<td>$0.95</td>
<td>$0.96</td>
<td>$47.50</td>
<td>$480.0K</td>
<td>6.9K</td>
<td>5.0K</td>
</tr>
<tr>
<td>NEM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$0.98</td>
<td>$0.95</td>
<td>$0.95</td>
<td>$47.50</td>
<td>$475.0K</td>
<td>6.9K</td>
<td>5.0K</td>
</tr>
<tr>
<td>NEM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$1.74</td>
<td>$1.65</td>
<td>$1.65</td>
<td>$52.50</td>
<td>$81.7K</td>
<td>11.6K</td>
<td>1.0K</td>
</tr>
<tr>
<td>NEM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$2.62</td>
<td>$2.52</td>
<td>$2.62</td>
<td>$55.00</td>
<td>$78.6K</td>
<td>3.3K</td>
<td>321</td>
</tr>
<tr>
<td>NEM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$6.35</td>
<td>$6.25</td>
<td>$6.35</td>
<td>$50.00</td>
<td>$63.5K</td>
<td>3.8K</td>
<td>138</td>
</tr>
</tbody>
</table>
</p>
<h3>About Newmont</h3>
<p>Newmont is the world's largest gold miner. It bought Goldcorp in 2019, combined its Nevada mines in a joint venture with competitor Barrick later that year, and also purchased competitor Newcrest in November 2023. Its portfolio includes 17 wholly or majority owned mines and interests in two joint ventures in the Americas, Africa, Australia and Papua New Guinea. The company is expected to produce roughly 6.9 million ounces of gold in 2024. However, after buying Newcrest, Newmont is likely to sell a number of its higher cost, smaller mines accounting for 20% of forecast sales in 2024. Newmont also produces material amounts of copper, silver, zinc, and lead as byproducts. It had about two decades of gold reserves along with significant byproduct reserves at the end of December 2023.</p>
<p>Having examined the options trading patterns of Newmont, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Newmont's Current Market Status</h3>
<ul>
<li>With a trading volume of 6,043,346, the price of NEM is up by 0.92%, reaching $54.02.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 34 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Newmont</h3>
<p>2 market experts have recently issued ratings for this stock, with a consensus target price of $61.5.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Argus Research has elevated its stance to Buy, setting a new price target at $58.<br />
&#x2A; Consistent in their evaluation, an analyst from UBS keeps a Buy rating on Newmont with a target price of $65. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Newmont with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Smart Money Is Betting Big In NEM Options

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Home Depot</strong>.</p>
<p>Looking at options history for Home Depot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>) we detected 8 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 37% of the investors opened trades with bullish expectations and 37% with bearish.</p>
<p>From the overall spotted trades, 2 are puts, for a total amount of $121,523 and 6, calls, for a total amount of $334,095.</p>
<h3>Predicted Price Range</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $355.0 to $400.0 for Home Depot during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In terms of liquidity and interest, the mean open interest for Home Depot options trades today is 1236.88 with a total volume of 931.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Home Depot's big money trades within a strike price range of $355.0 to $400.0 over the last 30 days.</p>
<h3>Home Depot Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726856288_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>HD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>09/20/24</td>
<td>$24.9</td>
<td>$23.75</td>
<td>$24.37</td>
<td>$365.00</td>
<td>$163.2K</td>
<td>1.5K</td>
<td style="text-align: right;">106</td>
</tr>
<tr>
<td>HD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$8.15</td>
<td>$7.9</td>
<td>$8.09</td>
<td>$390.00</td>
<td>$80.9K</td>
<td>189</td>
<td style="text-align: right;">120</td>
</tr>
<tr>
<td>HD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$16.6</td>
<td>$16.3</td>
<td>$16.3</td>
<td>$400.00</td>
<td>$40.7K</td>
<td>3.4K</td>
<td style="text-align: right;">40</td>
</tr>
<tr>
<td>HD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$3.35</td>
<td>$3.1</td>
<td>$3.1</td>
<td>$375.00</td>
<td>$40.6K</td>
<td>377</td>
<td style="text-align: right;">576</td>
</tr>
<tr>
<td>HD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$38.5</td>
<td>$38.05</td>
<td>$38.49</td>
<td>$360.00</td>
<td>$38.4K</td>
<td>1.2K</td>
<td style="text-align: right;">11</td>
</tr>
</tbody>
</table>
</p>
<h3>About Home Depot</h3>
<p>Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the US, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of Interline Brands in 2015 allowed Home Depot to enter the MRO business, which has been expanded through the tie-up with HD Supply (2020). The additions of the Company Store brought textiles to the lineup, and Redi Carpet added multifamily flooring, while the recent tie-up with SRS will help grow professional demand.</p>
<p>In light of the recent options history for Home Depot, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Present Market Standing of Home Depot</h3>
<ul>
<li>Trading volume stands at 1,950,580, with HD's price up by 0.18%, positioned at $391.06.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 53 days.</li>
</ul>
<h3>What Analysts Are Saying About Home Depot</h3>
<p>Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $383.3333333333333.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Loop Capital persists with their Hold rating on Home Depot, maintaining a target price of $360.<br />
&#x2A; Maintaining their stance, an analyst from Telsey Advisory Group continues to hold a Market Perform rating for Home Depot, targeting a price of $360.<br />
&#x2A; An analyst from DA Davidson persists with their Buy rating on Home Depot, maintaining a target price of $430. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Home Depot options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Behind the Scenes of Home Depot's Latest Options Trends

<p>Deep-pocketed investors have adopted a bearish approach towards Zillow Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/Z#NASDAQ">Z</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in Z usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for Zillow Gr. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 30% leaning bullish and 50% bearish. Among these notable options, 4 are puts, totaling $192,224, and 6 are calls, amounting to $369,411.</p>
<h3>Expected Price Movements</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $42.5 to $70.0 for Zillow Gr over the last 3 months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Zillow Gr's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Zillow Gr's substantial trades, within a strike price spectrum from $42.5 to $70.0 over the preceding 30 days.</p>
<h3>Zillow Gr 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726856282_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Z</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$1.91</td>
<td>$1.8</td>
<td>$1.81</td>
<td>$70.00</td>
<td>$87.6K</td>
<td>3.0K</td>
<td style="text-align: right;">47</td>
</tr>
<tr>
<td>Z</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/20/24</td>
<td>$14.75</td>
<td>$14.55</td>
<td>$14.66</td>
<td>$52.50</td>
<td>$73.3K</td>
<td>926</td>
<td style="text-align: right;">64</td>
</tr>
<tr>
<td>Z</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$1.4</td>
<td>$1.35</td>
<td>$1.35</td>
<td>$62.50</td>
<td>$67.5K</td>
<td>1.4K</td>
<td style="text-align: right;">9</td>
</tr>
<tr>
<td>Z</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$24.9</td>
<td>$24.7</td>
<td>$24.9</td>
<td>$42.50</td>
<td>$67.2K</td>
<td>327</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Z</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$8.15</td>
<td>$8.1</td>
<td>$8.1</td>
<td>$70.00</td>
<td>$66.4K</td>
<td>259</td>
<td style="text-align: right;">85</td>
</tr>
</tbody>
</table>
</p>
<h3>About Zillow Gr</h3>
<p>Zillow Group Inc is an Internet-based real estate company that offers its customers an on-demand experience for selling, buying, renting, or financing with transparency and ease The group works with real estate agents, brokers, builders, property managers, and landlords to pair technology with top-notch service. The group has brands such as Zillow, Trulia, StreetEasy, Hotpads, Zillow Rentals, Zillow Home Loans, ShowingTime, Follow Up Boss, Aryeo and others.</p>
<h3>Present Market Standing of Zillow Gr</h3>
<ul>
<li>With a trading volume of 2,423,245, the price of Z is up by 0.74%, reaching $68.34.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 40 days from now.</li>
</ul>
<h3>Expert Opinions on Zillow Gr</h3>
<p>In the last month, 1 experts released ratings on this stock with an average target price of $80.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Showing optimism, an analyst from Wedbush upgrades its rating to Outperform with a revised price target of $80. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Zillow Gr, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Decoding Zillow Gr's Options Activity: What's the Big Picture?

<p><strong>SkyBridge Capital</strong> founder <strong>Anthony Scaramucci</strong>, a headline speaker at Benzinga&#8217;s Future of Digital Assets event, is actively working with a group of cryptocurrency advocates to shape U.S. Vice President <strong>Kamala Harris</strong>&#8216;s policies on digital assets <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40934959/anthony-scaramucci-says-donald-trump-is-a-polarizing-person-but-pulling-democrats-along-on">ahead of the 2024 elections</a>.</p>
<p><strong>What Happened</strong>: "There's a group of cryptocurrency advocates, bitcoin advocates etc. that are working alongside her to distance the Democratic Party away from Elizabeth Warren and [Gary Gensler],&#8221; he said at <strong>TOKEN2049 </strong>event on Thursday.</p>
<p>Scaramucci's involvement in Harris's campaign will take center stage during his upcoming appearance at Benzinga's <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19, where he will join a panel to discuss the future of crypto regulation in the U.S. and beyond. </p>
<p>The event is expected to highlight key conversations around how digital assets are being positioned by political leaders in the run-up to the elections.</p>
<p>Scaramucci's team aims to sway Harris away from anti-crypto figures like Senator <strong>Elizabeth Warren</strong> and SEC Chair <strong>Gary Gensler</strong>, who have been leading voices in favor of strict regulations and crackdowns on the crypto industry. </p>
<p>According to Scaramucci, Harris has been engaging with crypto proponents and has discussions scheduled for the near future. </p>
<p>&#8220;I believe that we are making progress, and I think it's going in the right direction,&#8221; he said, optimistic about the vice president's willingness to consider industry-friendly policies.</p>
<p>While Harris's campaign team has yet to comment on these developments, Scaramucci's advocacy for her campaign signals an interesting shift in political strategy, especially given his past ties with former President <strong>Donald Trump</strong>. </p>
<p>Scaramucci, who served as Trump's Communications Director for six days in 2017, has since distanced himself, even calling Trump &#8220;a grifter&#8221; during a 2022 interview.</p>
<p><figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/27091545/Benzinga-conference.gif" alt="Benzinga future of digital assets conference" class="wp-image-267246" /></a></figure></p>
<p><strong>Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40961791/the-biggest-crypto-crime-cases-in-2024-heists-frauds-and-multi-million-dollar-scams-shake-">The Biggest Crypto Crime Cases In 2024: Heists, Frauds, And Multi-Million Dollar Scams Shake The Industry</a></strong></p>
<p>Ironically, Trump has become a vocal supporter of the crypto industry in recent months. </p>
<p>During a keynote at the <strong>Bitcoin </strong>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) Conference in Nashville this past July, Trump promised to protect federal Bitcoin holdings and hinted at plans to turn the U.S. into the <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40734266/trump-promised-to-turn-the-u-s-into-the-crypto-capital-of-the-world-but-did-he-actually-fo">"crypto capital of the planet&#8221;</a>.</p>
<p>His family also recently launched World Liberty Financial, a project with ambitions to <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40905315/donald-trumps-new-crypto-project-world-liberty-financial-everything-you-need-to-know">establish a crypto banking platform.</a></p>
<p>Despite his strained relationship with Trump, Scaramucci applauded the former president's stance on crypto, noting, &#8220;Whatever my feelings are about President Trump, I applaud him for understanding how important this industry is for the United States.&#8221; He also pointed out the unintended consequence: &#8220;Ironically, he's pulling the Democrats along into a centrist position on regulation.&#8221;</p>
<p>Scaramucci emphasized that he and other crypto insiders working with Harris want to ensure that digital asset policies don't become a partisan issue. "We want crypto in the U.S. to have a bipartisan standard unstrained from political and tribal conflicts," he said.</p>
<p>This ongoing political discourse will be a major focus of Scaramucci's panel at Benzinga's <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19, where he'll discuss the future of crypto regulation alongside other industry leaders.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40959531/oops-arthur-hayes-realizes-790-000-loss-on-this-ethereum-based-altcoin">Oops! Arthur Hayes Realizes $790,000 Loss On This Ethereum-Based Altcoin</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Anthony Scaramucci Backs Kamala Harris On Crypto Policy, Says 'It's Going In The Right Direction'

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>While technology lately has been framed in the context of computer hardware or software, it can also apply to the broader field of medicine. Therefore, investors should consider the viable field of MedTech stocks. According to a McKinsey &amp; Company report, over the next five years, the industry may see the <a href="https://www.mckinsey.com/industries/life-sciences/our-insights/what-to-expect-from-medtech-in-2024#:~:text=Going%20into%202024%2C%20we%20expect,among%20the%20fastest%2Dgrowing%20segments.">fastest growth</a> in the realms of cardiovascular health, digital healthcare and robotics.</p>



<p>Overall, the MedTech ecosystem <a href="https://www.futuremarketinsights.com/reports/medtech-market">reached a valuation of $503.2 billion last year</a>, per Future Market Insights. By 2033, the sector could be worth nearly $776.5 billion. If so, the expansion would imply a compound annual growth rate (CAGR) of 4.4%. Fundamentally, chronic conditions such as diabetes, cardiovascular disease and obesity are on the rise globally. Therefore, MedTech stocks will likely benefit from burgeoning relevance.</p>



<p>While it may be tempting to view the medical innovation space cynically, we should also note that chronic disease imposes a collective economic impact. Therefore, these MedTech stocks offer a win-win for everyone.</p>



<h2>Johnson &amp; Johnson (JNJ)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/jnj1600-300x169.jpg" alt="Negative Press Presents a Buying Opportunity with JNJ Stock"><div>Source: Sundry Photography / Shutterstock.com</div></div><p>A global healthcare juggernaut, <strong>Johnson &amp; Johnson</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/jnj-stock-quote/"><strong>JNJ</strong></a>) focuses on two primary segments after spinning off its consumer health productions division: pharmaceuticals and medical devices. The latter segment covers areas such as orthopedics, surgery, interventional solutions and vision care. As a top-tier name in MedTech stocks, J&amp;J benefits from its brand footprint and generally predictable revenue streams.</p>



<p>Financially, the company probably wouldn&rsquo;t be classified as remarkable. However, what investors should appreciate is that it gets the job done. In the past year since the second quarter, J&amp;J posted an average earnings per share of $2.62. That&rsquo;s above the collective consensus estimate over the period of $2.54, yielding an earnings surprise of 3.28%.</p>



<p>To be fair, JNJ stock isn&rsquo;t cheap, <a href="https://finance.yahoo.com/quote/JNJ/key-statistics/">trading hands at 4.5X trailing-year sales</a>. However, it&rsquo;s a modest premium over the past year&rsquo;s average metric of 4.39X. Further, analysts see slow and steady expansion of the business over the next two years. By the end of fiscal 2025, <a href="https://finance.yahoo.com/quote/JNJ/analysis/">EPS could be $10.71 on revenue of $91.11 billion</a>. Last year, these metrics sat at $9.92 on $85.16 billion.</p>



<h2>Abbott Laboratories (ABT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/abt1600-300x169.jpg" alt="Abbott (ABT) sign with lighting behind letters"><div>Source: testing / Shutterstock.com</div></div><p>A diversified healthcare enterprise, <strong>Abbott Laboratories</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/abt-stock-quote/"><strong>ABT</strong></a>) features solutions in diagnostics, nutrition, pharmaceuticals and medical devices. It&rsquo;s one of the most popular names among MedTech stocks thanks to its vast product portfolio, particularly for cardiovascular and diabetes care. Notably, its FreeStyle Libre brand of continuous glucose monitoring systems make Abbott a key player in managing chronic conditions.</p>



<p>As with Johnson &amp; Johnson above, Abbott doesn&rsquo;t particularly generate impressive financials. However, it&rsquo;s a reliable entity. In the past year since Q2, the company posted an average EPS of $1.11. This figure pipped the consensus view by two pennies, yielding an <a href="https://finance.yahoo.com/quote/ABT/analysis/">earnings surprise of 2.6%</a>.</p>



<p>ABT stock isn&rsquo;t super pricey in terms of valuation but it&rsquo;s not cheap. Right now, shares trade at 4.5X sales. However, the market previously accepted a revenue multiple of 4.54X. In that sense, Abbott appears fairly valued.</p>



<p>Looking out to year&rsquo;s end, analysts see EPS rising by 5% to $4.66. On the top line, sales could see a 4.1% lift to $41.74 billion. Add in a 2.1% forward yield and you have the makings of one of the top MedTech stocks.</p>



<h2>Edwards Lifesciences (EW)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/03/health-medical-heart-1600-300x169.jpg" alt="hands holding a red heart shape against blue background symbolizing health"><div>Source: shutterstock.com/Anastasia Zagoruyko</div></div><p>Billed as a specialist in the field for addressing structural heart diseases, <strong>Edwards Lifesciences</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/ew-stock-quote/"><strong>EW</strong></a>) focuses on developing heart valve replacement technologies and critical care monitoring systems. The company stands at the forefront of cardiovascular innovation. In particular, its minimally invasive heart valve replacement solution offers a literal lifeline for patients.</p>



<p>Financially, it must be stated that Edwards isn&rsquo;t as impressive as other major MedTech stocks. In Q3 and Q4 of last year, the company only met <a href="https://finance.yahoo.com/quote/EW/analysis/">earnings expectations</a>. However, it did beat bottom-line targets in the subsequent two quarters. Overall, the average EPS came out to 65 cents, beating the consensus average of 64 cents.</p>



<p>Another factor to consider is the higher premium. Presently, EW stock trades at 6.72X trailing-year sales. While elevated among peers, the market previously accepted a multiple of 9.09X in the past year.</p>



<p>Notably, analysts are looking at EPS expansion of almost 8% to $2.70 by year&rsquo;s end. Also, the top line could rise to $6.39 billion, up 6.4%.</p>



<h2>Glaukos (GKOS)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/12/eye-1600-300x169.jpg" alt="A close-up of someone's eye"><div>Source: Shutterstock</div></div><p>An ophthalmic pharmaceutical enterprise, <strong>Glaukos</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/gkos-stock-quote/"><strong>GKOS</strong></a>) develops devices and therapeutics for the treatment of glaucoma, corneal disorders and retinal diseases. To note, Glaukos is one of the pioneers in the field of micro-invasive glaucoma surgery or MIGS. Its innovative approach combined with certain less-invasive treatment options make GKOS an attractive idea for MedTech stocks.</p>



<p>Glaukos represents one of the riskier ideas in the sector. For one thing, it&rsquo;s not profitable. Moreover, in the past year since Q1 2024, the company incurred a loss per share of 60 cents. That&rsquo;s worse than the anticipated 56 cents in the red, yielding a negative &ldquo;earnings&rdquo; surprise of 7%.</p>



<p>Also, the price-to-sales ratio of nearly 18X may be tough to swallow. It&rsquo;s also up from the prior year&rsquo;s average metric of 11.9X. So, why bother with GKOS stock?</p>



<p>Analysts are looking for <a href="https://finance.yahoo.com/quote/GKOS/analysis/">robust growth</a> in the years ahead. By the end of fiscal 2025, sales could hit $451.62 million. That&rsquo;s up significantly from last year&rsquo;s print of $314.71 million. For speculators, Glaukos could rank among the MedTech stocks to gamble on.</p>



<h2>Inari Medical (NARI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/red-blood-cells-1600-300x169.png" alt="Red blood cells."><div>Source: Corona Borealis Studio / Shutterstock</div></div><p>Based in Irvine, California, <strong>Inari Medical</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/nari-stock-quote/"><strong>NARI</strong></a>) develops minimally invasive catheter-based devices to treat venous diseases. These include blood clots and deep vein thrombosis. One of the company&rsquo;s mainline products is called LimFlow, which is designed for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical options.</p>



<p>Another higher-risk, higher-reward idea among MedTech stocks, Inari lacks consistent profitability. It posted great results in Q2 and Q3 of last year. However, the subsequent two quarters have been messy. Overall, the average loss per share in the past four quarters came out to 5 cents. However, experts were anticipating a loss of 8 cents per share.</p>



<p>On the top line, Inari is a bit pricey for a MedTech player, trading hands at 5.89X sales. That said, in the past year this metric stood at 7.54X. It&rsquo;s conceivable that NARI stock might rise to its prior valuation.</p>



<p>By the end of 2024, analysts are looking for revenue of $598.72 million. If so, that would imply a growth rate of 21.3%, making NARI an intriguing idea for MedTech stocks to buy.</p>



<h2>iRhythm Technologies (IRTC)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/love-heart-stock-money-300x169.png" alt="Stacks of gold coins increasing in amount lead up to a big red heart"><div>Source: Shutterstock</div></div><p>A digital healthcare company, <strong>iRhythm Technologies</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/irtc-stock-quote/"><strong>IRTC</strong></a>) engages in the design, development and commercialization of device-based tech. These solutions provide ambulatory cardiac monitoring services to diagnose arrhythmias. The company is known for its Zio Monitor patch, which offers a more convenient and comprehensive mechanism to detect arrhythmias.</p>



<p>Moving into an even riskier space for the possibility of greater rewards, iRhythm isn&rsquo;t a profitable company. Indeed, during the past four quarters, the MedTech specialist incurred a loss per share of $1. That was conspicuously worse than the expected red ink of 74 cents, yielding a negative surprise of 35%.</p>



<p>To be sure, IRTC stock isn&rsquo;t a screaming deal either in the revenue front, trading at 5.3X sales. However, in the past year, this metric stood at 7.34X. Again, it&rsquo;s possible that with some positive catalyst, IRTC may rise to its former valuation.</p>



<p>Analysts are hoping for exactly that, with fiscal 2024 sales <a href="https://finance.yahoo.com/quote/IRTC/analysis/">possibly landing at $583.5 million</a>. That would be up 18.4% from the prior year&rsquo;s tally of $492.68 million. It&rsquo;s one of the MedTech stocks to consider if you&rsquo;re the gambling type.</p>



<h2>SI-Bone (SIBN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/hospital1600-300x169.jpg" alt="Image of a hospital with workers walking in the halls"><div>Source: Shutterstock</div></div><p>A medical device firm that operates in the field of musculoskeletal disorders, <strong>SI-Bone</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/sibn-stock-quote/"><strong>SIBN</strong></a>) is relevant but also highly speculative. As one of the smaller MedTech stocks available, SIBN&rsquo;s price action is subject to extreme volatility. That said, the fundamentals are compelling. SI-Bone offers minimally invasive surgical implants for the treatment of sacroiliac joint dysfunction.</p>



<p>As you might imagine, SI-Bone has difficulty with the profitability department. In the past four quarters, the company posted an average loss per share of 27 cents. Still, analysts anticipated during this time that the average loss would land at 33 cents. So, technically speaking, the average surprise came out to 18%.</p>



<p>Regarding sales, SIBN trades at 4.19X revenue. That&rsquo;s not terrible but it&rsquo;s not great by any means. However, in the past year, the metric stood at loftier 6.15X. Under the right conditions, SI-Bone could rise to its former valuation.</p>



<p>Analysts are aiming for such a reality to materialize, broadcasting a <a href="https://finance.yahoo.com/quote/SIBN/analysis/">sales target of $165.05 million</a> by year&rsquo;s end. That&rsquo;s up 18.8% from the prior year. In the following year, revenue could pop again to $191.54 million, potentially enticing market gamblers.</p>



<p><em>On the date of publication, Josh Enomoto</em><em> did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;</em><em>The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em><em></em></p>



<p><em>On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<div><p>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>
<p>The post <a href="https://investorplace.com/2024/07/7-leading-medtech-stocks-for-next-gen-health-solutions/">7 Leading MedTech Stocks for Next-Gen Health Solutions</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

7 Leading MedTech Stocks for Next-Gen Health Solutions

Inari Medical (NARI – Research Report) received a Buy rating and a $68.00 price target from Deutsche Bank analyst Pito Chickering today. The compan...

Inari Medical (NARI) Receives a New Rating from Deutsche Bank

Penumbra Grinding Through A Painful Growth Expectations Reset

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Inari Medical (NARI – Research Report) and PROCEPT B...

Analysts Offer Insights on Healthcare Companies: Inari Medical (NARI) and PROCEPT BioRobotics (PRCT)

Kallum Titchmarsh, an analyst from Morgan Stanley, maintained the Buy rating on Inari Medical (NARI – Research Report). The associated price target...

Inari Medical's Resilience and Market Potential Affirm Buy Rating

Mike Kratky, an analyst from Leerink Partners, has initiated a new Hold rating on Inari Medical (NARI). Mike Kratky's rating is based on the dynami...

Inari Medical: Navigating Competitive Threats and Growth Potential in Venous Thromboembolism Treatment

Morgan Stanley analyst Kallum Titchmarsh has maintained their bullish stance on NARI stock, giving a Buy rating on August 28. Kallum Titchmarsh has...

Inari Medical: A Strong Buy on Robust Product Reception and Promising Financial Outlook

In a report released on September 6, Larry Biegelsen from Wells Fargo assigned a Buy rating on Inari Medical (NARI – Research Report), with a price...

Inari Medical: Strong Buy Rating Amidst Anticipated Growth Catalysts and Market Expansion

In a report released today, Adam Maeder from Piper Sandler maintained a Hold rating on Inari Medical (NARI – Research Report), with a price target ...

Piper Sandler Keeps Their Hold Rating on Inari Medical (NARI)

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Inari Medical (NARI – Research Report) yesterday and set a price target of $65.00. L...

Buy Rating for Inari Medical Amid Positive PEERLESS Trial Outlook and Revenue Growth Potential

GKOS

IRTC

PRCT

SIBN

Legal

Press Releases

NARI Investors Have Opportunity to Lead Inari Medical, Inc. Securities Fraud Lawsuit with the Schall Law Firm

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Inari

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Inari Medical, Inc. – NARI

Inari Medical to Announce Second Quarter 2024 Financial Results

Inari Medical Reports Second Quarter 2024 Financial Results

Management

Inari Medical Announces Chief Financial Officer Retirement and Succession Plan

Inari Medical to Present at Upcoming Investor Conferences

Inari Medical Announces PEERLESS Data to be Presented During the Late-Breaking Clinical Trial Sessions at TCT 2024

Kaskela Law LLC Announces Shareholder Investigation of Inari Medical, Inc. (NASDAQ: NARI) and Encourages Investors to Contact the Firm

Kaskela Law LLC Announces Shareholder Investigation of Inari Medical, Inc. (NASDAQ: NARI) and Encourages Long-Term NARI Shareholders to Contact the Firm

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Inari Medical

Inari Medical (NARI) Forecast

Inari Medical (NASDAQ:NARI) Stock, Quote.Headers.trade-ideas